The DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index; 134 of the 178 sources its claims cite were checked for support.
IMPlications of IMP2 in RNA Biology and Disease
Open accessAbstract
Insulin-like growth factor 2 mRNA-binding protein 2 (IMP2) is an RNA-binding protein that positively regulates m6A-modified RNAs involved in critical cellular processes such as metabolism, oncogenesis, and immune function. Here, we elucidate facets of IMP2 biology, including several mechanisms of action on RNA, factors that regulate IMP2 expression, its relevant biological target RNAs, its role in normal development and disease, and its potential as a therapeutic target. IMP2 is a multi-level regulator of metabolism, influencing pathways linked to diabetes, obesity, and adipose function. Through genomic amplification and transcriptional overexpression in cancer cells, IMP2 can drive the initiation and progression of multiple cancer types, and high expression is associated with decreased overall survival of patients with cancer. IMP2 influences normal immune function, inflammation, macrophage polarization, and tumor immune evasion. IMP2 has emerged as a promising therapeutic target, particularly for cancers and metabolic diseases.
Overview
CoChat Summary
## TL;DR
This review synthesizes how IMP2/IGF2BP2 acts as an m6A-dependent RNA-binding protein that regulates RNA stability, translation, and sometimes splicing across metabolism, cancer, and immunity. The paper argues that IMP2 is broadly oncogenic and metabolically important, while also highlighting context-specific exceptions such as its tumor-suppressive role in clear cell renal cell carcinoma.
## Key findings
- IMP2 is described as a multi-level regulator of metabolism and disease: it influences diabetes, obesity, adipose function, wound healing, fatty liver disease, cancer, immune function, inflammation, macrophage polarization, and tumor immune evasion.
- In cancer, IGF2BP2 is reported as genomically altered in over 2% of all cancers, with cBioPortal-curated rates including 18% ovarian, 14% cervical, 9% lung, 8% uterine, 5% esophageal/gastric, 4% head and neck, 3% prostate, 3% bladder, 2.8% testicular, 2.8% skin, 2.5% breast, 1.5% colon, 1.3% soft tissue, and 0.8% pancreatic cancers.
- Pan-cancer survival analysis found high IGF2BP2 mRNA associated with worse overall survival in several cancers, including KIRC (HR = 2.1), HNSC (HR = 2.01), SARC (HR = 2.24), PAAD (HR = 3.21), UCEC (HR = 1.94), LUAD (HR = 1.57), LIHC (HR = 1.68), BLCA (HR = 1.54), and KIRP (HR = 2.03); it was associated with better survival in OV (HR = 0.74) and THCA (HR = 0.2).
- In type 2 diabetes, the review reports GWAS links to rs4402960 and rs1470579, and states that pancreatic β-cell-specific IGF2BP2 deletion in mice impaired insulin secretion and reduced compensatory β-cell proliferation under high-fat diet challenge.
## Methods
- This is a review article, not an original experimental study; it synthesizes prior work on IMP2 biology across metabolism, cancer, and immunology.
- The review draws on multiple evidence types cited in the text, including GWAS, pan-cancer database analyses (e.g., GEPIA2, cBioPortal, Kaplan–Meier Plotter), mouse knockout/transgenic models, and cell-based assays such as RIP, RNA pull-down, luciferase reporter assays, RNA stability assays, and xenograft studies.
- The main analysis is narrative integration of these studies to describe IMP2 mechanisms, regulation, target RNAs, and disease relevance.
## Limitations
- The paper explicitly states that it has not been determined whether SNPs in the IMP2 region are causative of T2D phenotypes or whether they share haplotype blocks with other causative elements.
- The review also notes that some reported effects may be context-dependent or partially explained by off-targets, for example where anti-proliferative effects of IMP2 inhibitors were only partially rescued by biallelic IGF2BP2 knockout.
- Evident from the text: because this is a review, many conclusions are drawn from heterogeneous prior studies across different models and tumor types, so direct comparability is limited.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Venn diagram showing the number of overlapping and independent target RNAs regulated by IMP1, IMP2, and IMP3. CLIP-seq and other sequencing data from the POSTAR3 database [10]. Figure created in Python 3.11.0 using the matplotlib_venn library and Adobe Illustrator version 27.9.](https://figures.cochat.ai/paper-figures/da9a332d4ad547b6bb8476cf114f4a75/implications-of-imp2-in-rna-biology-and-disease-figure-2.jpg)


![Figure 5 Genomic and transcriptional changes to IGF2BP2 in cancer. (A) Rate of IGF2BP2 genomic alterations in tumor samples. Data from the cBioPortal curated set of non-redundant studies [77,78,79]. (B) Cancers with decreased expression relative to normal tissue of IGF2BP2 messenger RNA in log2(TPM+1) from tumor (T) relative to normal tissue (N) from the GEPIA2 database [81]. Log fold change between tumor and normal tissue: ACC (−2.66), BRCA (−1.78), and KIRC (−1.95). (C) Cancers with increased expression relative to normal tissue of IGF2BP2 messenger RNA in log2(TPM+1) from tumor (T) relative to normal tissue (N) from the GEPIA2 database [81]. Log fold change between tumor and normal tissue: ESCA (3.74), HNSC (2.85), UCS (2.27), GBM (2.16), PAAD (1.94), OV (1.84), STAD (1.77), READ (1.73), TGCT (1.56), COAD (1.47), SKCM (1.32), LIHC (1.13), LUSC (1.12). See the Abbreviations section for definitions of acronyms. Figure adapted in Adobe Illustrator version 27.9.](https://figures.cochat.ai/paper-figures/4ef2809e4a024799a7cbbd66abeac7bd/implications-of-imp2-in-rna-biology-and-disease-figure-5.jpg)
![Figure 6 Kaplan–Meier analysis of cancers where higher IGF2BP2 expression is significantly associated with decreased (A–I) or increased (J–K) overall survival; data was obtained from Kaplan–Meier Plotter [82,83]. Patients were stratified into high and low IGF2BP2 expression groups based on median expression of IGF2BP2. Only cancers where IGF2BP2 is significantly associated with survival are displayed: KIRC (A), HNCSC (B), SARC (C), PAAD (D), UCEC (E), LUAD (F), LIHC (G), BLCA (H), KIRP (I), THCA (J), and OV (K). Please see the Abbreviations section for definitions of acronyms. Figure adapted in Adobe Illustrator version 27.9.](https://figures.cochat.ai/paper-figures/7b87895f36654739a0ef9ddb9f761ee0/implications-of-imp2-in-rna-biology-and-disease-figure-6.jpg)
Verification
Claims the paper makes
105 Valid · 13 Not valid · 28 Not checked · 9 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Phylogenetically conserved RRM domains on readers are responsible for IMP2 identifying m6A marks on RNA [17,27].”
§ IMPlications of IMP2 in RNA Biology and Disease > 1. Introduction > 1.2. Mechanisms of Action
What the sources say
- Partly supportedcites [17] Jiang, 2021, The Role of m6A Modification in the Biological Functions and Diseases, Signal Transduct. Target. Ther. sourceExperimental — accuracy not yet measured
In “The writers, erasers, and readers of m6A” (page unavailable), the paper identifies IGF2BP2 as an m6A reader and says the IGF2BP family has two RRM domains and binds transcripts containing an m6A motif. It does not say that the RRM domains are responsible for IMP2’s recognition of m6A; its specific account of RRM-mediated recognition concerns a different reader, hnRNP A2/B1. (LLM, conf=0.88)
- Disputedcites [27] Chen, Y., Zhou, Z., Chen, Y., and Chen, D. (2024). Reading the m6A-Encoded Epitranscriptomic Information in Development and Diseases. Cell Biosci., 14. sourceExperimental — accuracy not yet measured
The 'IGF2BP family of m6A readers' section says IGF2BP2 has RRM and KH domains, but assigns m6A-site recognition predominantly to the third and fourth KH domains. It says the RRM domains instead help stabilize IGF2BP–RNA complexes, contrary to the claim that they are responsible for IMP2 identifying m6A marks. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Homozygous IGF2BP2 knockout in lung cells led to a complete halt of proliferation [85].”
§ IMPlications of IMP2 in RNA Biology and Disease > 3. Cancer > 3.5. Lung Cancer
What the sources say
- Disputedcites [85] Chanda, S., Lepikhov, K., Dahlem, C., Schymik, H.S., Hoppstädter, J., Geber, A.-K., Wagner, K., Kessler, S.M., Empting, M., and Kiemer, A.K. (2024). Gene Editing and Small Molecule Inhibitors of the RNA Binding Protein IGF2BP2/IMP2 Show Its Potential as an Anti-Cancer Drug Target. Front. Biosci. (Landmark Ed.), 29. sourceExperimental — accuracy not yet measured
The Discussion (§4) says biallelic IGF2BP2/IMP2 knockout LLC1 lung-cell clones continued to grow: three grew more slowly than a control, while one grew faster. The Abstract says edited A549 lung cells lost the ability to proliferate, but the authors could not generate a biallelic knockout in that line. Thus, the paper does not report a complete halt of proliferation following homozygous knockout in lung cells. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Reader proteins, including IGF2BP proteins and the YTH domain family (e.g., YTHDF1, YTHDF2, YTHDF3, and YTHDC1) proteins, recognize m6A-modified transcripts and modulate their stability and translation [2,26].”
§ IMPlications of IMP2 in RNA Biology and Disease > 1. Introduction > 1.2. Mechanisms of Action
What the sources say
- Supportedcites [2] Huang, 2018, Recognition of RNA N6-Methyladenosine by IGF2BP Proteins Enhances mRNA Stability and Translation, Nat. Cell Biol. source
The Introduction identifies YTH-domain proteins and IGF2BPs as m6A readers and says they regulate mRNA fate through translation, decay, or stabilization. The Discussion likewise reports that IGF2BPs stabilize target mRNAs and facilitate their translation. The source supports the sentence’s broad claim, although it does not individually discuss every YTH protein listed as an example. (LLM, conf=0.91)
- Partly supportedcites [26] Wang, 2014, N6-Methyladenosine-Dependent Regulation of Messenger RNA Stability, Nature sourceExperimental — accuracy not yet measured
The main-text passage labeled Abstract (page unavailable) reports m6A-selective binding by YTHDF1–3, and the Abstract reports that YTHDF2 regulates mRNA decay and moves bound mRNA out of the translatable pool. The copy does not establish the claimed roles for IGF2BP proteins or YTHDC1, or show that YTHDF1 and YTHDF3 modulate stability and translation. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The KH3/4 domains have an anti-parallel pseudo-dimer orientation.”
§ IMPlications of IMP2 in RNA Biology and Disease > 1. Introduction > 1.2. Mechanisms of Action
What the sources say
- Partly supportedcites [15] Zorc, S., Munoz-Tello, P., O’Leary, T., Yu, X., Nag, M., Hansel-Harris, A., Forli, S., Griffin, P.R., Kojetin, D.J., and Roy, R.N. (2024). Structural Insights into IMP2 Dimerization and RNA Binding. bioRxiv. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports that structural analyses of human IGF2BP1 KH3/4 suggest an anti-parallel pseudo-dimer conformation. The claim states this as an established orientation without the paper’s qualification that it is suggested for IGF2BP1; the paper does not establish it for IMP2 KH3/4. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The specificity of target selection among IMP family members is influenced by variations in the KH3/4 domains [6].”
§ IMPlications of IMP2 in RNA Biology and Disease > 1. Introduction > 1.1. IMP Family of RNA-Binding Proteins
What the sources say
- Supportedcites [6] Biswas, 2019, The Structural Basis for RNA Selectivity by the IMP Family of RNA-Binding Proteins, Nat. Commun. source
The Discussion states that mutations in KH-domain variable loops account for differences in RNA sequence specificity between ZBP1 and IMP2. Its account of KH3/4 selection further says that specific variable-loop amino acid mutations mediated the difference in selected RNA targets. The supplied passages do not give page numbers. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
67 more claims · 47 with their cited sources checked
Create a free account to see all 155 claims and to verify the 19 references still open.
- Probably not a substantial claim. 14
- It may state two separate claims as one. 75
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Zhang, 2022, N6-Methyladenosine (m6A) Reader IGF2BP2 Promotes Gastric Cancer Progression via Targeting SIRT1, Bioengineered, 13, 11541, 10.1080/21655979.2022.2068920”
Cited work 10.1080/21655979.2022.2068920 · retracted 2026-10-01 · notice 10.1080/21655979.2026.2729938 · this paper published 2025-03-07
Citations
Cites
1 retracted
Zhang, Z., Xing, Y., Gao, W., Yang, L., Shi, J., Song, W., & Li, T. (2022) · Bioengineered · doi:10.1080/21655979.2022.2068920 · Cited by 34
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“This phenomenon, also known as the Warburg effect, enables cancer cells to rapidly generate energy and biomass precursors even in the presence of oxygen, supporting their accelerated proliferation and survival in harsh tumor microenvironments [76].”
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 5×
“Genomicalterations18%[77–79],overexpressed[81], increasedsurvival[82,83].”
InfluentialIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis
Tang, Z., Kang, B., Li, C., Chen, T., & Zhang, Z. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz430 · Cited by 5,083 · cited 8×
“Genomicalterations18%[77–79],overexpressed[81], increasedsurvival[82,83].”
InfluentialTopology of the human and mouse m6A RNA methylomes revealed by m6A-seq
Dominissini, D., Moshitch-Moshkovitz, S., Schwartz, S., Salmon-Divon, M., Ungar, L., Osenberg, S., Cesarkas, K., Jacob-Hirsch, J., Amariglio, N., Kupiec, M., et al. (2012) · Nature · doi:10.1038/nature11112 · Cited by 4,884 · cited 2×
“This distribution pattern is largely consistent across different cell types and tissues [30,31].”
N6-methyladenosine-dependent regulation of messenger RNA stability
Wang, X., Lu, Z., Gomez, A., Hon, G. C., Yue, Y., Han, D., Fu, Y., Parisien, M., Dai, Q., Jia, G., et al. (2014) · Nature · doi:10.1038/nature12730 · Cited by 4,558 · cited 1×
“Reader proteins, including IGF2BP proteins and the YTH domain family (e.g., YTHDF1, YTHDF2, YTHDF3, and YTHDC1) proteins, recognize m6A-modified tran-Int scripts and modulate their stability and translation [2,26].”
Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop Codons
Meyer, K. D., Saletore, Y., Zumbo, P., Elemento, O., Mason, C. E., & Jaffrey, S. R. (2012) · Cell · doi:10.1016/j.cell.2012.05.003 · Cited by 4,223 · cited 1×
“This distribution pattern is largely consistent across different cell types and tissues [30,31].”
N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO
Jia, G., Fu, Y., Zhao, X., Dai, Q., Zheng, G., Yang, Y., Yi, C., Lindahl, T., Pan, T., Yang, Y.-G., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.687 · Cited by 4,106 · cited 1×
“The m6A modification can be removed by erasers, mainly FTO and ALKBH5 [24,25].”
ALKBH5 Is a Mammalian RNA Demethylase that Impacts RNA Metabolism and Mouse Fertility
Zheng, G., Dahl, J. A., Niu, Y., Fedorcsak, P., Huang, C.-M., Li, C. J., Vågbø, C. B., Shi, Y., Wang, W.-L., Song, S.-H., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.10.015 · Cited by 3,550 · cited 1×
“The m6A modification can be removed by erasers, mainly FTO and ALKBH5 [24,25].”
Cited by
Li, L., Cui, Y., Ji, Y., Ma, K., Lin, X., Liu, T., Sun, J., Liu, H., Guo, J., & Li, M. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06093-5 · Cited by 4
“Insulin-like growth factor 2 mRNA-binding protein 2 (IMP2/IGF2BP2), a key reader in the m 6 A process, is abnormally expressed in T2DM, obesity and cancer [15].”
Co-expression network analysis reveals repression of Igf2bp2 by REV-ERBβ in skeletal musclePreprint
Vishnu, A. M., Zhang, Q., Srivastava, S., Koronowski, K. B., & Srivastava, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.13.724827
Profibrotic macrophage populations and cell communications in pulmonary fibrosis
Zhang, D., Zhao, W., Xu, C., Du, L., & Liu, Q. (2026) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-026-01179-x
Metadata
- Authors
- Das, J., Busia-Bourdain, O., Khan, K. M., & Wolfe, A. L.
- Affiliations
- The Graduate Center, CUNY (US)
- City University of New York (US)
- Corresponding author
- Wolfe, Andrew L.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2025-03-07
- Volume
- 26
- Issue
- 6
- Pages
- 2415
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11942581
- OpenAlex
- W4408226515
- Semantic Scholar
- e40a3ca7c770e56d3fa51c842186504c3aa272f2
- Cited by
- 3
- References
- 154
- Citations by year
- 2026: 3
- FWCI
- 0.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (U54CA221704, R00CA226363, 2318923, ENHC55171)
- Hunter College of the City University of New York (U54CA221704, R00CA226363, 2318923, ENHC55171)
- National Science Foundation (U54CA221704, R00CA226363, 2318923, ENHC55171)
- PSC-CUNY Research (U54CA221704, R00CA226363, 2318923, ENHC55171)
- Oncogenuity, Inc. (U54CA221704, R00CA226363, 2318923, ENHC55171)
- DASNY GRTI (U54CA221704, R00CA226363, 2318923, ENHC55171)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Keywords
- IGF2BP2, RNA-binding proteins, m6A RNA methylation, RNA metabolism, cancer, metabolic disorders, diabetes mellitus, obesity, adipose tissue, gene amplification, carcinogenesis, tumor immune evasion, macrophage polarization, inflammation, therapeutic target
- MeSH terms
- Animals, Humans, Neoplasms, RNA, RNA-Binding Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IMPlications of IMP2 in RNA Biology and Disease. https://app.cochat.ai/papers/10.3390/ijms26062415
- The paper
- Das, J., Busia-Bourdain, O., Khan, K. M., & Wolfe, A. L. (2025). IMPlications of IMP2 in RNA Biology and Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062415
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.